Skip to main content
Edward Libby, MD, Hematology, San Diego, CA

EdwardNLibbyMD

Hematology San Diego, CA

Physician

Dr. Libby is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Libby's full profile

Already have an account?

  • Office

    9333 Genesee Ave
    San Diego, CA 92121
    Phone+1 800-926-8273

Summary

  • Dr. Libby received his B.S. from the University of Texas at El Paso and his M.D. from the University of Texas Health Science Center at Houston. He completed his Internal Medicine residency and chief residency at the University of New Mexico(UNM) in Albuquerque. He was a Fellow in Hematology at UNM and at UNC Chapel Hill.

Education & Training

  • University of New Mexico School of Medicine
    University of New Mexico School of MedicineFellowship, Hematology and Medical Oncology, 2002 - 2005
  • University of New Mexico School of Medicine
    University of New Mexico School of MedicineResidency, Internal Medicine, 1984 - 1987
  • McGovern Medical School at UTHealth
    McGovern Medical School at UTHealthClass of 1984

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2024 - 2026
  • WA State Medical License
    WA State Medical License 2011 - 2026
  • OR State Medical License
    OR State Medical License 2023 - 2025
  • WI State Medical License
    WI State Medical License 2024 - 2025
  • DC State Medical License
    DC State Medical License 2022 - 2024
  • NM State Medical License
    NM State Medical License 1985 - 2013
  • American Board of Internal Medicine Hematology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Validation of the PRIMA-Prognostic Index for Patients Treated with Rituximab Plus Chemotherapy and Refinement of Prognostic Parameters for Patients on Rituximab Plus L...
    Edward N. Libby III, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage ...
    Edward N. Libby III, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • The HAS-RISC Score for Venous Thromboembolism (VTE) Risk Stratification in Newly Diagnosed Multiple Myeloma Patients Starting Immunomodulatory Drugs (IMID) 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Treating Cancer Differently in Older Patients
    Treating Cancer Differently in Older PatientsSeptember 10th, 2015

Professional Memberships